Inovio Pharmaceuticals, Inc. (NASDAQ:INO) went up by 35.88% from its latest closing price compared to the recent 1-year high of $33.79. The company’s stock price has collected 80.24% of gains in the last five trading sessions.
Is It Worth Investing in Inovio Pharmaceuticals, Inc. (NASDAQ :INO) Right Now?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) scored a price-to-earnings ratio above its average ratio, recording x from its present earnings ratio. Plus, the 36-month beta value for INO is at 1.10. Opinions of the stock are interesting as 2 analysts out of 8 who provided ratings for Inovio Pharmaceuticals, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $19.71, which is -$18.52 below the current price. INO currently public float of 164.19M and currently shorts hold a 31.56% ratio of that float. Today, the average trading volume of INO was 31.76M shares.
INO’s Market Performance
INO stocks went up by 80.24% for the week, with a monthly jump of 23.14% and a quarterly performance of 34.01%, while its annual performance rate touched 637.85%. The volatility ratio for the week stands at 16.51% while the volatility levels for the past 30 days are set at 11.53% for Inovio Pharmaceuticals, Inc.. The simple moving average for the period of the last 20 days is 56.18% for INO stocks with a simple moving average of 70.85% for the last 200 days.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with ROTH Capital repeating the rating for INO by listing it as a “Sell.” The predicted price for INO in the upcoming period, according to ROTH Capital is $11 based on the research report published on July 1st of the current year 2020.
Maxim Group, on the other hand, stated in their research note that they expect to see INO reach a price target of $11. The rating they have provided for INO stocks is “Hold” according to the report published on July 1st, 2020.
H.C. Wainwright gave a rating of “ Neutral” to INO, setting the target price at $11 in the report published on June 29th of the current year.
INO Trading at 5.13% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.19% of loss for the given period.
Volatility was left at 11.53%, however, over the last 30 days, the volatility rate increased by 16.51%, as shares surge +30.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.12% lower at present.
During the last 5 trading sessions, INO rose by +80.24%, which changed the moving average for the period of 200-days by +634.92% in comparison to the 20-day moving average, which settled at $12.07. In addition, Inovio Pharmaceuticals, Inc. saw 461.21% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at INO starting from Humeau Laurent, who sold 19,467 shares at the price of $19.06 back on Aug 10. After this action, Humeau Laurent now owns 43,966 shares of Inovio Pharmaceuticals, Inc., valued at $371,004 using the latest closing price.
Kim Jong Joseph, the Chief Executive Officer of Inovio Pharmaceuticals, Inc., sold 100,000 shares at $21.13 during a trade that took place back on Jul 30, which means that Kim Jong Joseph is holding 1,188,313 shares at $2,113,450 based on the most recent closing price.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -2855.31 for the present operating margin
The net margin for Inovio Pharmaceuticals, Inc. stands at -2902.75. The total capital return value is set at -122.34, while invested capital returns managed to touch -127.11. Equity return is now at value -217.80, with -82.40 for asset returns.
Based on Inovio Pharmaceuticals, Inc. (INO), the company’s capital structure generated 2,896.79 points at debt to equity in total, while total debt to capital is 96.66. Total debt to assets is 65.46, with long-term debt to equity ratio resting at -14.77. Finally, the long-term debt to capital ratio is 2,836.39.
When we switch over and look at the enterprise to sales, we see a ratio of 82.13, with the company’s debt to enterprise value settled at 0.29. The receivables turnover for the company is 1.35 and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.94.